Leading the Way in Life Science Technologies

GEN Exclusives

More »

Best of the Web

More »
Nov 15, 2013 (Vol. 33, No. 20)

Medcko.com

URL:www.medcko.com
  • Nice site organization, large number of topics
  • Incomplete disease directory, no citations for content

Once you find your way to this site, you will be rewarded with an abundance of information about fitness, healthy living, and diseases. Visitors can explore the site by categories such as Eating and Dieting, Mental Health, or Diseases and Conditions; alternatively, one can search the website for a specific disease, condition, symptom, or medication. Unfortunately, while the collection of diseases included on the site is impressive, it is not comprehensive. (Some glaring omissions included Parkinson’s Disease and Alzheimer’s Disease.) For those conditions that are included on the site, readers will get to browse information about causes, diagnosis, follow up, prevention, risk, symptoms, and treatment.

  • Key:
  • Strong Points
  • Weak Points
  • Ratings:
  • Excellent
  • Very Good
  • Good


*The opinions expressed are solely those of the author(s) and should not be construed as reflecting the viewpoints of the publisher, Genetic Engineering & Biotechnology News, Mary Ann Liebert, Inc., the publishing house, or employees and affiliates thereof.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »